Chapter
Chapter 1. Embryological Mechanisms of Maldescent and Tumourigenesis
Aetiology of cryptorchidism in the human
Effect of Undescended Testis
Chapter 2. The Epidemiological Association between Undescended Testis, Inguinal Hernia and Testicular Cancer: Results from the U.K. National Case-Control Study of Testicular Cancer
Chapter 3. The Epidemiology of Cryptorchidism: Results from the John Radcliffe Hospital Cryptorchidism Study
John Radcliffe Hospital Cryptorchidism Study
Discussion and Conclusions
Chapter 4. Maldescent and Cryptorchidism: A Rational Approach to Management
Chapter 5. Recent Progress in Research on CIS in Adults. Biological Aspects and Screening
Possible fetal origin of CIS cells
Progression from CIS to invasive cancer
Prevalence of CIS in different population groups
Screening and management of CIS
Perspectives for the future
Chapter 6. Simultaneous Bilateral Testicular Tumours
Chapter 7. Are Paediatric Germ Cell Tumours Germ Cell Tumours?
Chapter 8. Pathology and Cytogenetics of Germ Cell Tumours in Children
Germ Cell Tumours of Indeterminate Behaviour
Malignant Germ Cell Tumours
Malignant mixed germ cell tumours (MMGCTs)
Extragonadal germ cell tumours (EGGCTs)
Genetics of germ cell tumours
Chapter 9. UKCCSG Studies of Paediatric Germ Cell Tumours
Chapter 10. Changing Pattern of Incidence and Survival in Children with Germ Cell Tumours (GCTs)
Chapter 11. Testicular Non-Seminomatous Germ Cell Tumour (TGMnS) French Society of Pediatric Oncology Experience (SFOP), 1985–1989
Chapter 12. Chemotherapy Associated Toxicity in Patients with Malignant Non Testicular Germ Cell Tumours (MNGCTs). Comparison of MAKEI 83/86 and MAKEI 89
Chapter 13. Germ Cell Tumours in Children: A Report of 84 Cases
Chapter 14. Paediatric Germ Cell Tumours in the West Midlands Health Authority Region (WMHAR): Increasing Incidence and Pattern of Geographical Distribution
Chapter 15. Gonadotrophin and Sex Hormone Levels in Testis Cancer Patients with and without Carcinoma In Situ of the Contralateral Testis
Chapter 16. Contralateral Biopsies in Patients with Testicular Germ Cell Tumour —The German Experience
Chapter 17. Seminal Fluid Analysis and Carcinoma-In-Situ of the Testis
Chapter 18. Abdominal CT Scans in Patients with Retroperitoneal Germ Cell Tumours with or without Carcinoma In Situ
Chapter 19. The Value of Testicular Biopsy as a Screening Procedure for Future Malignant Germ Cell Tumours in Infertile Men
Chapter 20. Interphase Cytogenetics of Testicular Germ Cell Tumours: Clonal Origin of Seminoma and Nonseminoma Components in Combined Tumours
Chapter 21. Growth of Human Seminoma Cells on STO Feeder Depends on Phenotype, Presence of Fetal Calf Serum and Added Growth Factors
Chapter 22. Molecular Genetics in Germ Cell Tumours
Lessons From Cytogenetics
A Novel Model of Origin of Germ Cell Tumours
Novel Tumour Suppressor Genes on 12q
Does KIT/MGF Deregulation Underlie Nonseminomatous Differentiation?
Genetic Loss and Somatic Differentiation of Teratomas
Gene Amplification in Germ Cell Tumours
Chapter 23. Mediastinal Germ Cell Tumours
Chapter 24. The Origin of Non-Germ Cell Tumour Elements within Germ Cell Tumours and Midline Tumours of Uncertain Histogenesis
Chapter 25. Unusual Neoplasms Detected in Testis Cancer Patients Undergoing Post Chemotherapy Retroperitoneal Lymphadenectomy
Chapter 26. Outcome Analysis for Patients with Persistent Non-Seminomatous Germ Cell Tumour in Post-Chemotherapy Retroperitoneal Lymph Node Dissections
Chapter 27. The Wilms' Tumour 1 Gene in Testicular Cancer Patients
Chapter 28. Image Analysis Quantitation of p53 Gene Product and Ki-67 in Testicular Germ Cell Tumours — A Quantitative Immunohistochemical Study
Chapter 29. Is Apoptosis an Important Mode of Death in Embryonal Carcinoma?
Chapter 30. Growth Inhibition and Differentiation of a Human Embryonal Carcinoma (EC) Cell Line by Osteogenic Protein-1 (OP-1)
Chapter 31. Revised International Histological Classification of Testicular Tumours
II. Sex Cord/Stromal Tumours
III. A. Tumours and Tumour-Like Lesions Containing Both Germ Cells and Sex/Cord Stromal Elements
Ill B. Tumour-Like Lesion Composed of Various Constituents of the Gonad
IV., V., VI. Miscellaneous Tumours, Haematopoietic Tumours, and Secnodary Tumours
VII. Tumours of Collecting Ducts, Rete, Epididymis, Spermatic Cord, Capsule, Supporting Structures and Appendices
Chapter 32. New Classification of Germ Cell Tumours
Chapter 33. Discussion on the Classification of Germ Cell Tumours
Chapter 34. Grading Germ Cell Tumours as a Means to Resolve the Last Twenty Five Years Transatlantic Conflict over Testis Tumour Classification
Chapter 35. The Clinical Value of Imaging Germ Cell Tumours with Radiolabeled Antibodies
Chapter 36. The Role of Positron Emission Tomography in the Assessment of Germ Cell Tumours
Chapter 37. The Princess Margaret Hospital Experience in the Management of Stage I and II Seminoma — 1981 to 1991
Chapter 38. Chemotherapy of Seminoma
Chapter 39. Late Relapse in Patients on Surveillance for Stage I Testicular Seminoma
Chapter 40. Surveillance of Stage 1 Non-Seminomatous Testicular Cancer — A Preliminary Report of the EORTC GU-Cooperative Group Surveillance Study
Chapter 41. Short Course Adjuvant Chemotherapy in High Risk Stage I Non-Seminomatous Germ Cell Tumours of the Testis (NSGCTT): An MRC Study Report
Chapter 42. One Course Adjuvant Treatment for Stage 1 Germ Cell Tumours
Chapter 43. NSGCT Stage I — Adjuvant Chemotherapy for Patients with Vascular Invasion and Surveillance for Patients without Vascular Invasion: Update of a Prospective Trial after 8 Years
Surveillance (= no vascular invasion) patients
Adjuvant chemotherapy (= vascular invasion) patients
Chapter 44. Testicular Cancer in Russia
Chapter 45. Good Risk Chemotherapy Trials for Patients with Advanced Germ Cell Tumours: The MSKCC Experience
Chapter 46. Carboplatin-Based Chemotherapy in Good Prognosis Metastatic Non-Seminoma of the Testis (NSGCT): An Interim Report of an MRC/EORTC Randomised Trial
Chapter 47. Insurance Status as a Prognostic Factor for Stage and Survival of Testicular Cancer Patients in Illinois
Chapter 48. Prognostic Factors in Metastatic Seminoma and Non-Seminomatous Germ Cell Tumours
Chapter 49. Prognostic Factors in Disseminated Non- Seminomatous Testicular Cancer
Chapter 50. Predictors of Residual Mass Histology Following Chemotherapy for Metastatic Nonseminomatous GCT: Univariate and Multivariate Meta-Analysis
Chapter 51. Resection of Small Masses of Residual NSGCT and Subsequent Therapy: Dilemmas in Clinical Decision Making
Chapter 52. Needs, Findings and Outcome of Post-Chemotherapy Surgery of Residual Masses (RM) in Patients with Non-Seminomatous Germ Cell Testis Tumours (NSGCTT) at a Single Institution
Part I: Treatment of Brain Metastases Round Table
Chapter 53. Treatment of Central Nervous System (CNS) Metastases of Non-Seminomatous Germ Cell Tumours: The Charing Cross Experience
Chapter 54. Treatment of Cerebral Metastases from Malignant Germ Cell Tumours
Chapter 55. Management of Central Nervous System Metastases in Patients with Disseminated Germ Cell Tumours
Chapter 56. The Treatment of Brain Metastases from Germ Cell Cancer — A Report of the Round-Table Discussion
Chapter 57. Dose Intensive Chemotherapy for Poor Prognosis Germ Cell Malignancies
TABLE 1 ELIGIBILITY CRITERIA INCLUSION CRITERIA
Chapter 58. Schedule Intensive Treatment for Testicular Germ Cell Tumours
Chapter 59. Salvage Therapy in Metastatic Non-Seminomatous Germ Cell Tumour at the University of Texas M.D. Anderson Cancer Center
Chapter 60. Late Relapses in Advanced Malignant Germ Cell Tumours (MGCT) Treated with Cisplatin Based Chemotherapy
Chapter 61. The Importance of Dose Intensity in the Chemotherapy of Advanced Testicular Cancer
Part II: Salvage Chemotherapy and ABMT Round Table
Chapter 62. Salvage Chemotherapy and Autologous Bone Marrow Transplantation: 9-Year Experience at Institut Gustave-Roussy
Chapter 63. Dose-Intensive Chemotherapy in Patients with Germ Cell Tumours: The Memorial Sloan-Kettering Cancer Center Experience
PROGNOSTIC FACTORS FOR SALVAGE THERAPY
CONCLUSIONS/FUTURE DIRECTIONS
Chapter 64. A High-Dose Carboplatin-Based Salvage Strategy for Relapsing or Refractory Germ Cell Cancer
Chapter 65. High Dose Chemotherapy with Autologous Marrow Rescue for Germ Cell Salvage Consolidation: Vancouver Experience
Chapter 66. Management of Recurrent Germ Cell Tumours: Role of High Dose Chemotherapy
Chapter 67. High Dose Chemotherapy with Haemopoietic Stem Cell Support
Chapter 68. Salvage Chemotherapy and Autologous Bone Marrow Chemotherapy for Refractory Germ Cell Malignancies
Chapter 69. High Dose Chemotherapy Plus Stem Cell Support for Poor Risk Testicular Cancer or as Salvage Therapy for Patients with Relapsed Disease
Chapter 70. Salvage Chemotherapy and Autologous Stem Cell/Bone Marrow Transplantation in Germ Cell Cancer — Summary of Papers Presented and Round-Table Discussion
Chapter 71. Surgery in Non-Seminomatous Germ Cell Tumours of the Testis
Chapter 72. Aortic Replacement in Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Cancer
Chapter 73. Resection of the Inferior Vena Cava or Intraluminal Tumour Thrombectomy During Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Cancer: Indications and Results
Chapter 74. Retroperitoneal Surgery: Management Strategies in Malignant Teratoma
Elective surgery - 33 patients
Interventional surgery - 5 patients
Relapsed disease - 7 patients
Chapter 75. Modified Retroperitoneal Lymph Node Dissection for Testicular Tumour: Open and Laparoscopic Approach, Operative Technique and Results
Chapter 76. Late Side Effects in Patients Treated for Testicular Cancer
Gastrointestinal toxicity
Second non-germ cell malignancy
Sexuality, infertility and paternity
Chapter 77. Fertility in Nerve-Sparing RPLND
Chapter 78. Treatment for Loss of Ejaculation after Para-Aortic Lymphadenectomy
Chapter 79. Second Cancer Risk Following Testicular Cancer
The Dutch study of second cancer risk following testicular cancer
Directions for future research
Chapter 80. Long-Term Toxicity after Cisplatinum-Based Chemotherapy
Chapter 81. Experience of a Testicular Cancer Patient Support Group
Chapter 82. Severe Vascular Side Effects of Cisplatinum Based Chemotherapy
Chapter 83. Haemopoietic Growth Factors: An Overview
Chapter 84. Development of New Antiemetics
Nausea and vomiting induced by chemo- and radiotherapy
Limitations of traditional antiemetic regimens
The discovery of the 5-HT3 receptor antagonists
Characteristics of the 5-HT3 receptors
The role of the 5-HT3 receptor
The development of the 5-HT3 receptor antagonists as antiemetic agents
The antiemetic sites of action of 5-HT3 receptor antagonists
Chemotherapy, 5-hydroxytryptamine and emesis
The role of the 5-HT3 receptor antagonists as antiemetic agents in man
5-HT3 receptor antagonists: The cost effective advance in chemotherapy
Future potential of antiemetic therapy
Chapter 85. Strategies to Control Vomiting Caused by Anticancer Drugs
MANAGEMENT O F ACUTE AND DELAYED EMESIS
Chapter 86. Chemotherapy for Testicular Cancer: Prophylactic Ciprofloxacin Reduces the Incidence of Neutropenic Pyrexia
Chapter 87. Germ Cell Tumours: Past, Present and Future
Part III: Abstracts of Poster Presentations
Chapter 88. Is there any Relationship between Vasectomy and Testicular Cancer?
Vasectomy - it's effect on health
Vasectomy and testicular cancer
Conclusions and future studies
Chapter 89. Primary Cerebral Germinoma in Children — French Society of Paediatric Oncology (SFOP) Experience
Chapter 90. NSGCTT Metastases
Chapter 91. A Pilot Evaluation of Peripheral Blood Stem Cell Transplants Compared to ABMT Following High Dose Chemotherapy
Chapter 92. Clinical Features and Prognosis of Primary Mediastinal and Retroperitoneal Germ Cell Tumours Treated with Cisplatin-Based Chemotherapy
Chapter 93. Four Drug Combination Chemotherapy Consisting of Etoposide, Cisplatin, Bleomycin and Cyclophosphamide for Advanced Metastatic Non-Seminomatous Germ Cell Tumours
Chapter 94. Germ Cell Tumours and Carcinoma In Situ of the Testis Detected by Fine Needle Biopsy
Chapter 95. Malignant Sex Cord/Stromal Tumours: A Case Report of a Metastatic Sertoli-Leydig Cell Tumour of the Testis
Chapter 96. Phase III Trial of Early Intensified Chemotherapy (HDCT) with Autologous Bone Marrow Transplantation (ABMT) in First Line Treatment of Poor Risk Non-Seminomatous Germ Cell Tumours (NSGCT): Long Term Results of a Randomised Trial
Chapter 97. Estimation of 12p Copy Number in Paraffin-Embedded Tissue Sections of Germ Cell Tumours by In Situ Hybridization of a Microdissected 12p Probe
Chapter 98. An Evaluation of a Testicular Self-Examination Video
Chapter 99. High Dose Chemotherapy with Autologous Bone Marrow Transplantation for Advanced Germ Cell Tumours
Chapter 100. Localised Gonadal Non-Seminomatous Germ Cell Tumours — French Society of Pediatric Oncology Experience (SFOP)
Chapter 101. Salvage Therapy in Refractory/Relapsed Germ Cell Tumours: Etoposide, Ifosfamide and Cisplatin (VIP)
Chapter 102. Preliminary Results of BOP—VIP Protocol in Poor Risk "Worst Prognosis" Non-Seminomatous Germ Cell Tumours of Testis
Chapter 103. Cancer in Cryptorchid Testes at IRCH All India Institute of Medical Sciences, New Delhi 1987–1992
Chapter 104. Weekly Cisplatinum Combination Chemotherapy Regimes for Relapsed/Poorly Responding Metastatic Malignant Germ Cell Tumours
Chapter 105. The Results of a Surveillance Study in Stage I Non-Seminomatous Germ Cell Tumours of the Testis
Chapter 106. HCG Positive Seminoma
Germ Cell Tumours III
：Proceedings of the Third Germ Cell Tumour Conference Held in Leeds, UK, on 8th—10th September 1993
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
